Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Essa Pharma (NQ: EPIX )

2.870 -0.080 (-2.71%)
Streaming Delayed Price Updated: 9:46 AM EDT, Aug 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,688
Open 2.920
Bid (Size) 2.870 (69)
Ask (Size) 2.880 (4)
Prev. Close 2.950
Today's Range 2.860 - 2.920
52wk Range 2.410 - 14.88
Shares Outstanding 44,073,076
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
ESSA Pharma And 2 Other Penny Stocks Insiders Are Aggressively Buying
Tesla Inc (NASDAQ: TSLA) posted better-than-expected earnings for its second quarter, while sales missed estimates. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
$1.7 Million Bet On This Biotechnology Stock? 3 Penny Stocks Insiders Are Buying
U.S. stock futures traded higher this morning after recording losses in the previous session. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga

Performance

YTD
-80.12%
-80.12%
1 Month
-9.18%
-9.18%
3 Month
-50.52%
-50.52%
6 Month
-70.59%
-70.59%
1 Year
-63.25%
-63.25%

More News

Read More
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Highs On Tuesday
Via Benzinga
The Daily Biotech Pulse: Kezar Life Surges On Positive Kidney Disease Trial Data, FDA Rejects Spero Therapeutics' Tebipenem, Graybug Reviews Strategic Alternatives
Via Benzinga
ESSA Pharma's EPI-7386 Monotherapy / Combo Therapy Show Early Activity Against Prostate Cancer
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Via Benzinga
ESSA Pharma: Q2 Earnings Insights
Via Benzinga
ESSA Pharma Announces First Patient Dosed In Phase 1/2 Clinical Trial Of EPI-7386 In Combination With Enzalutamide In Patients With Metastatic Castration-Resistant Prostate Cancer
Via Benzinga
70 Biggest Movers From Friday
Via Benzinga
ESSA Pharma, Caris Life Sciences Ink Liquid Biopsy Profiling Pact
Via Benzinga
46 Biggest Movers From Yesterday
Via Benzinga
Mid-Afternoon Market Update: Dow Turns Positive; Sesen Bio Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
60 Biggest Movers From Yesterday
Via Benzinga
Mid-Day Market Update: Crude Oil Down Over 2%; Travere Therapeutics Shares Jump
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
38 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Mid-Morning Market Update: Markets Open Lower; Empire State Manufacturing Index Dips In August
Via Benzinga
Topics Stocks
Exposures US Equities
Short Interest Report: AMC Short Interest Slides While That Of Workhorse Spikes
Via Talk Markets
78 Biggest Movers From Friday
Via Benzinga
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
The Daily Biotech Pulse: Moderna's Vaccine Authorized In Japan, Neovasc's Adverse Ruling In Germany, Metacrine Rallies On Insider Buying
Via Benzinga
Stocks That Hit 52-Week Highs On Wednesday
Via Benzinga
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.